“Proliferative vitreoretinopathy (PVR) can develop after ocular trauma or inflammation and is a common complication of surgery to correct retinal detachment.
Currently, there are no pharmacological treatments for PVR.
Cannabinoids acting at cannabinoid 2 receptor (CB2R) can decrease inflammation and fibrosis.
The objective of this study was to examine the anti-inflammatory actions of CB2R as a candidate novel therapeutic target in experimental PVR.
In conclusion, our results indicate that intervention at early stage PVR with CB2R agonists reduces ocular inflammation and disease severity.
CB2R may represent a therapeutic target to prevent PVR progression and vision loss.”